The financials
OPKO Health, Inc. by the numbers
OPKO Health, Inc. (OPK) reported revenue of $124M in Q1 2026 (quarter ended Mar 31, 2026), down 17% from the same quarter a year earlier. That came with a gross margin of 37% and net loss of $55M. For the full year FY2025, revenue was $607M (−15% year on year) and net income −$226M. Its largest product in Jun 2026 was Service at $75M, 40% of the disclosed total, ahead of Intellectual Property And Other at 25%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $124M | $150M | −17% |
| Gross profit | $46M | $43M | +7.4% |
| Operating income | −$51M | −$67M | n/a |
| Net income | −$55M | −$68M | n/a |
| Diluted EPS | −$0.07 | −$0.10 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Service | $75M | 40% |
| Intellectual Property And Other | $46M | 25% |
| Transfer Of Intellectual Property And Other | $46M | 25% |
| Rayaldee | $14M | 7.6% |
| Royalty | $6.4M | 3.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $187.4M (+66%)
Transfer Of Intellectual Property And Other grew +208% year on yearService -26% year on year
Segment Latestquarter on quarteryear on year
- Service$74.5M$74.5MQoQ +3.3%year on year -26%+3.3%-26%
- Intellectual Property And Other$46.1M$46.1MQoQ +229%year on year +207%+229%+207%
- Transfer Of Intellectual Property And Other$46.1M$46.1MQoQ +230%year on year +208%+230%+208%
- Rayaldee$14.3M$14.3MQoQ +11%year on year -1.8%+11%-1.8%
- Royalty$6.4M$6.4MQoQ -year on year +4.9%-+4.9%
Diagnostics & Research
Ranks #16 of 17 by Smart Score